Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anixa Biosciences

2.81
+0.03001.08%
Post-market: 2.810.00000.00%17:00 EDT
Volume:16.44K
Turnover:45.81K
Market Cap:90.47M
PE:-7.14
High:2.83
Open:2.77
Low:2.75
Close:2.78
Loading ...

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

PR Newswire
·
30 Apr

BRIEF-Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent

Reuters
·
14 Apr

Anixa Biosciences Inc - Receives Notice of Allowance for CAR-T Technology Patent

THOMSON REUTERS
·
14 Apr

Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine

MT Newswires Live
·
10 Apr

BRIEF-Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office

Reuters
·
09 Apr

Anixa Biosciences Receives Notice of Allowance From U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
09 Apr

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

PR Newswire
·
09 Apr

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Benzinga
·
09 Apr

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Mar

Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines

MT Newswires Live
·
25 Mar

BRIEF-Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Reuters
·
25 Mar

Anixa Biosciences Enters Letter of Intent With Verdi Solutions to Develop Artificial Intelligence-Guided Personalized and off-the-Shelf Cancer Vaccines

THOMSON REUTERS
·
25 Mar

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Benzinga
·
25 Mar

Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Anixa Biosciences: Buy Rating Affirmed Amid Patent Approval and Clinical Trial Advancements

TIPRANKS
·
25 Mar

Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine

MT Newswires Live
·
24 Mar

BRIEF-Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Reuters
·
24 Mar

Anixa Biosciences Receives Notice of Allowance From Uspto for Ovarian Cancer Vaccine

THOMSON REUTERS
·
24 Mar

Anixa Biosciences Holds Annual Stockholder Meeting 2025

TIPRANKS
·
22 Mar

Anixa Biosciences Initiated at Buy by Maxim Group

Dow Jones
·
21 Mar